【homes for rent in boyle county ky】AstraZeneca's COVID-19 Vaccine Trial Delays May Worsen As FDA Widens Investigation
AstraZeneca Plc’s
(NYSE:
AZN
) coronavirus vaccine development program could hit by further delays,homes for rent in boyle county ky as the Food and Drug Administration has widened the scope of its probe into the halted trial, Reuters
reported
Wednesday.
What Happened:
The federal agency is inquiring whether side effects similar to the one seen in the COVID-19 vaccine trial — transverse myelitis — also emerged in trials of other vaccines designed by Oxford University, AstraZeneca's partner, Reuters said, citing people familiar with the matter.
The vaccines reportedly under review use a modified adenovirus as a vector and target illnesses such as the Middle East Respiratory Syndrome and the flu.
Oxford’s vaccines use a chimpanzee adenovirus, ChAdOx1, unlike other vaccine developers that use a human variant.
A review of research papers by Reuters found that in one trial, a serious side effect event cited by researchers was classified as unrelated to the vaccine.
Another complication that may affect the trial: the Reuters report said the FDA is requesting data from the British pharmaceutical firm that is in a different format than the one used by the FDA.
People familiar with the developments told Reuters the FDA’s actions aren't an indicator there are safety issues related to any of the vaccines under review.
Benzinga is covering every angle of how the coronavirus affects the financial world.
For daily updates,
sign up for our coronavirus newsletter
.
Why It Matters:
Last month, AstraZeneca’s coronavirus vaccine trials were halted after a volunteer developed symptoms of a serious
neurological disorder
known as transverse myelitis.
The Cambridge, United Kingdom-based company has resumed trials in India, South Africa, Brazil and the U.K.
Some scientists have questioned why the drugmaker’s COVID-19 vaccine trials remain suspended in the U.S.
While AstraZeneca experiences delays,
Pfizer Inc
(NYSE:
PFE
) is seeking FDA clearance to expand its late-stage trials by adding more participants.
AZN Price Action:
AstraZeneca shares ended Wednesday's session down 0.54% at $54.81 and fell slightly further after-hours.
See more from Benzinga
Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas
Regeneron Says COVID-19 Antibody Cocktail Helped Non-Hospitalized Patients Heal Faster In Early Trials
Sanofi CEO Says COVID-19 Vaccine Development Process Accelerated, Not Side-Stepped
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
View comments
相关文章
Cheap oil prices likely to reduce inflationary pressures in India: government adviser
By Manoj KumarNEW DELHI (Reuters) - A fall in global crude oil prices will likely reduce inflationar2024-09-29Huawei confident it will supply core network technology to European operators
COPENHAGEN (Reuters) - Chinese telecom equipment maker Huawei is confident some European telecoms fi2024-09-29Nio Deliveries Jump 109% In November, Boosts Production Capacity To Keep Pace With Rising Demand
Nio Inc – ADR(NYSE:NIO) reported Tuesday, ahead of the market open, another monthly record deliverie2024-09-29Sick of Roaming Fees? Now Your Carrier Is Hurting Too
(Bloomberg Opinion) -- The Covid-19 pandemic has revealed an uncomfortable truth about the telecoms2024-09-29Should You Sell in May or Buy 5 Top Coronavirus-Immune Stocks?
Wall Street is off to a weak start to May 2020 after the 82-year best April, reminding investors of2024-09-29- LOS ANGELES, CA / ACCESSWIRE / November 2, 2020 /The Schall Law Firm, a national shareholder rights2024-09-29
最新评论